RT Journal Article
SR Electronic
A1 Parry, Nicola
T1 TNT Results: Carboplatin Improves Patient Outcomes in Advanced BRCA1/2-Mutated BC
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 56
SP 6
OP 7
DO 10.1177/1559897715571062
UL http://mdc.sagepub.com/content/14/56/6.abstract
AB The randomized phase 3 TNT trial, conducted to compare the efficacy of 2 chemotherapy drugs, carboplatin and docetaxel, at treating patients with advanced triple-negative breast cancer, showed that although survival outcomes were similar with both drugs, carboplatin was more efficacious in patients with BRCA1/2 gene mutations.